Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells
Open Access
- 17 June 2002
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 195 (12), 1653-1659
- https://doi.org/10.1084/jem.20020338
Abstract
Induction of tumor-specific immunity requires that dendritic cells (DCs) efficiently capture and present tumor antigens to result in the expansion and activation of tumor-specific cytotoxic T cells. The transition from antigen capture to T cell stimulation requires a maturation signal; in its absence tolerance, rather than immunity may develop. While immune complexes (ICs) are able to enhance antigen capture, they can be poor at inducing DC maturation, naive T cell activation and protective immunity. We now demonstrate that interfering with the inhibitory signal delivered by FcgammaRIIB on DCs converts ICs to potent maturation agents and results in T cell activation. Applying this approach to immunization with DCs pulsed ex-vivo with ICs, we have generated antigen-specific CD8+ T cells in vivo and achieved efficient protective immunity in a murine melanoma model. These data imply that ICs may normally function to maintain tolerance through the binding to inhibitory FcgammaRs on DCs, but they can be converted to potent immunogenic stimuli by selective engagement of activating FcgammaRs. This mechanism suggests a novel approach to the development of tumor vaccines.Keywords
This publication has 39 references indexed in Scilit:
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in VivoThe Journal of Experimental Medicine, 2001
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- IgG Fc ReceptorsAnnual Review of Immunology, 2001
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Characterization of the ovalbumin‐specific TCR transgenic line OT‐I: MHC elements for positive and negative selectionImmunology & Cell Biology, 2000
- FcR γ chain deletion results in pleiotrophic effector cell defectsCell, 1994
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988
- Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.The Journal of Experimental Medicine, 1979